Shows Antiangiogenic Drug Therapy for Cancer Produces Mixed Results in Preclinical Models : Clinical Implications and Future Research Directions
نویسنده
چکیده
Dr. Robert Kerbel and his lab at Sunnybrook Research Institute have found that antiangiogenic drugs, shown to slow tumour growth in some cancer patients, might also accelerate metastasis in certain preclinical circumstances. The journal Cancer Cell published the results on March 3; here, Dr. John Ebos, a postdoctoral fellow in the Kerbel lab and lead author of the study, discusses what the findings mean for patients and the field of antiangiogenesis research.
منابع مشابه
Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
The tumor vasculature is an increasingly attractive target for development of anticancer drugs. The fundamental principle for antiangiogenic cancer therapy is based on the inhibitory effect of chemical compounds, proteins or nucleotides on tumor angiogenesis. Indeed, in almost all preclinical tumor models, antiangiogenic monotherapy with different agents shows potent effects on suppression of t...
متن کاملمطالعه میزان آنژیوژنز مدل‌های زنوگرافت بومی گلیوبلاستوما مالتی‌فورم در بیماران ایرانی به‌روش MVD-CD34
Background: Despite advances in cancer diagnosis and treatment, survival rate of patients suffering from glioblastoma multiform (GBM) has not been significantly improved. Therefore, novel therapeutic adjuncts to routine therapies have been suggested over time. Inhibition of angiogenesis by antiangiogenic drugs is one of the new approaches to inhibit the growth of malignant cells. Microvessel d...
متن کاملA model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
The failure rate of randomized phase III oncology clinical trials is extremely high, even when preceded by encouraging preclinical studies and phase II trial results of the same therapy. Thus, there is considerable effort being made to improve the predictive clinical potential of preclinical models, in addition to improving phase II trial design. With respect to the former, preclinical models h...
متن کاملPotential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
PURPOSE To resolve a controversy involving the therapeutic impact of antiangiogenic drugs and particularly antibodies targeting the VEGF pathway, namely, a body of preclinical mouse therapy studies showing such drugs can promote invasion and/or distant metastasis when used as monotherapies. In contrast, clinical studies have not shown such promalignancy effects. However, most such clinical stud...
متن کاملAntiangiogenesis and drug delivery to tumors: bench to bedside and back.
After over 30 years of preclinical and clinical development, antiangiogenic agents have recently entered the clinic as attractive targeted therapeutics for the treatment of cancer. Fueled by exciting new developments in the field, the AACR Special Conference was designed to broadly survey critical scientific advances in the antiangiogenic therapy of cancer. Because these advances have come prim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009